| Development of selective Clk1 and-4 inhibitors for cellular depletion of cancer-relevant proteins AK ElHady, M Abdel-Halim, AH Abadi, M Engel Journal of Medicinal Chemistry 60 (13), 5377-5391, 2017 | 46 | 2017 |
| Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism NS Ahmed, NH Elghazawy, AK ElHady, M Engel, RW Hartmann, ... European Journal of Medicinal Chemistry 112, 171-179, 2016 | 29 | 2016 |
| Development of novel amide–derivatized 2, 4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a … SS Darwish, M Abdel-Halim, AK ElHady, M Salah, AH Abadi, W Becker, ... European Journal of Medicinal Chemistry 158, 270-285, 2018 | 19 | 2018 |
| Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors AK ElHady, SP Shih, YC Chen, YC Liu, NS Ahmed, AB Keeton, GA Piazza, ... Bioorganic chemistry 98, 103742, 2020 | 15 | 2020 |
| Pharmacological inhibition of protein kinase C (PKC) ζ downregulates the expression of cytokines involved in the pathogenesis of chronic obstructive pulmonary disease (COPD) M Abdel-Halim, SS Darwish, AK ElHady, J Hoppstädter, AH Abadi, ... European Journal of Pharmaceutical Sciences 93, 405-409, 2016 | 15 | 2016 |
| Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects YT AlNajjar, M Gabr, AK ElHady, M Salah, G Wilms, AH Abadi, W Becker, ... European Journal of Medicinal Chemistry 227, 113911, 2022 | 13 | 2022 |
| An overview of cdc2‐like kinase 1 (Clk1) inhibitors and their therapeutic indications AK ElHady, DS El‐Gamil, AH Abadi, M Abdel‐Halim, M Engel Medicinal Research Reviews 43 (2), 343-398, 2023 | 11 | 2023 |
| Structure-based design of novel tetrahydro-beta-carboline derivatives with a hydrophilic side chain as potential phosphodiesterase inhibitors AK Elhady, SC Sigler, N Noureldin, JC Canzoneri, NS Ahmed, GA Piazza, ... Scientia Pharmaceutica 84 (3), 428-446, 2016 | 6 | 2016 |
| Development of novel conformationally restricted selective Clk1/4 inhibitors through creating an intramolecular hydrogen bond involving an imide linker DS El-Gamil, AK ElHady, PJ Chen, TL Hwang, AH Abadi, M Abdel-Halim, ... European Journal of Medicinal Chemistry 238, 114411, 2022 | 5 | 2022 |
| Discovery of hydroxybenzothiazole urea compounds as multitargeted agents suppressing major cytotoxic mechanisms in neurodegenerative diseases Y Aboushady, M Gabr, AK ElHady, M Salah, AH Abadi, G Wilms, ... ACS Chemical Neuroscience 12 (22), 4302-4318, 2021 | 5 | 2021 |
| 5-Methoxybenzothiophene-2-carboxamides as inhibitors of Clk1/4: optimization of selectivity and cellular potency AK ElHady, DS El-Gamil, PJ Chen, TL Hwang, AH Abadi, M Abdel-Halim, ... Molecules 26 (4), 1001, 2021 | 5 | 2021 |
| Discovery of novel 5-methoxybenzothiophene hydrazides as metabolically stable Clk1 inhibitors with high potency and unprecedented Clk1 isoenzyme selectivity DS El-Gamil, AK ElHady, PJ Chen, TL Hwang, AH Abadi, M Abdel-Halim, ... European Journal of Medicinal Chemistry 247, 115019, 2023 | 4 | 2023 |
| Melatonin–vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat YY Helmi, N Papenkordt, G Rennar, F Gbahou, AK El‐Hady, N Labani, ... Archiv der Pharmazie 356 (9), 2300149, 2023 | 3 | 2023 |
| Advancements in phosphodiesterase 5 inhibitors: unveiling present and future perspectives AK ElHady, DS El-Gamil, M Abdel-Halim, AH Abadi Pharmaceuticals 16 (9), 1266, 2023 | 1 | 2023 |
| Development of 5-hydroxybenzothiophene derivatives as multi-kinase inhibitors with potential anti-cancer activity YA Abd El-Rahman, PJ Chen, AK ElHady, SH Chen, HC Lin, DS El-Gamil, ... Future Medicinal Chemistry, 1-17, 2024 | | 2024 |
| Originally Designed Dyrk1a Inhibitors as Potent Dyrk1a/Clk1/Clk4/Haspin Multiple Inhibitors: Synthesis and Biological Activities of Sulfur-Containing Tetracycles A Faouzi, A Arnaud, F HALLE, J ROUSSEL, M AYMARD, V DENAVIT, ... | | |
Ashraf AbadiProfessor, Former Dean, Faculty of Pharmacy and Biotechnology, German University in CairoVerified email at guc.edu.eg
